[1] Canadian Cancer Society, “Canadian Cancer Statistics 2010,” Author, Toronto, 2010.
[2] D. S. McMeekin, K. M. Alektiar, P. J.Sabbatini and R. J. Zaino, “Corpus: Epithelial Tumors,” In: R. R. Barakat, M. Markman and M. E. Randall, Eds., Principles and Practice of Gynecologic Oncology, 5th Edition, Lippincott Williams & Wilkins, Baltimore, 2009, pp. 683-732.
[3] J. S. Kwon, M. S. Carey, E. F. Cook, F. Qiu and L. F. Paszat, “Addressing Wait Times for Endometrial Cancer Surgery in Ontario,” Journal of obstetrics and gynaecology Canada, Vol. 29, No. 12, 2007, pp. 982-987.
[4] K. R. Lee, F. A. Tavassoli, J. Prat, M. Dietel, D. J. Gersell, A. I. Karseladze, et al., “Tumours of the Ovary and Peritoneum,” In: F. A. Tavassoli and P. Devilee, Eds., World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs, IARC Press, Lyon, 2003, pp. 113-145.
[5] P. W. Dickman, A. Sloggett, M. Hills and T. Hakulinen, “Regression Models for Relative Survival,” Statistics in Medicine, Vol. 23, No. 1, 2004, pp. 51-64. doi:10.1002/sim.1597
[6] P. W. Dickman and H. O. Adami, “Interpreting Trends in Cancer Patient Survival,” Journal of Internal Medicine, Vol. 260, No. 2, 2006, pp. 103-117. doi:10.1111/j.1365-2796.2006.01677.x
[7] F. Ederer, L. M. Axtell and S. J. Cutler, “The Relative Survival Tart: A Statistical Methodology,” National Cancer Institute Monograph, Vol. 6, 1961, pp. 101-102.
[8] A. Pokhrel and T. Hakulinen, “How to Interpret the Relative Survival Ratios of Cancer Patients,” European Journal of Cancer, Vol. 44, No. 1, 2008, pp. 2661-2667. doi:10.1016/j.ejca.2008.08.016
[9] P. C. Lambert and P. Royston, “Further Development of Flexible Parametric Models for Survival Analysis,” The Stata Journal, Vol. 9, No. 2, 2009, pp. 265-290.
[10] P. Royston and M. K. Parmar, “Flexible Parametric Proportional-Hazards and Proportional-Odds Models for Censored Survival Data, with Application to Prognostic Modelling and Estimation of Treatment Effects,” Statistics in Medicine, Vol. 21, No. 15, 2002, pp. 2175-2197. doi:10.1002/sim.1203
[11] Statistics Canada, “Table 102-0504: Deaths and Mortality Rates, by Age Group and Sex, Canada, Provinces and Territories, Annual (2112 Series),” Statistics Canada, 2010.
[12] S. Durrleman and R. Simon, “Flexible Regression Models with Cubic Splines,” Statistics in Medicine, Vol. 8, No. 5, 1989, pp. 551-561. doi:10.1002/sim.4780080504
[13] Statistics Canada, “Table 051-0001: Population by Sex and Age Group, by Province and Territory,” Statistics Canada, 2010. http://www40.statcan.gc.ca/l01/cst01/demo31c-eng.htm
[14] C. M. Beard, L. C. Hartmann, G. L. Keeney, C. S. Crowson, G. D. Malkasian, P. C. O’Brien, et al., “Endometrial Cancer in Olmsted County, MN: Trends in Incidence, Risk Factors and Survival,” Annals of Epidemiology, Vol. 10, No. 2, 2000, pp. 97-105. doi:10.1016/S1047-2797(99)00039-3
[15] A. Jensen, H. Sharif and S. K. Kjaer, “Use of Fertility Drugs and Risk of Uterine Cancer: Results from a Large Danish Population-Based Cohort Study,” American Journal of Epidemiology, Vol. 170, No. 11, 2009, pp. 1408-1414. doi:10.1093/aje/kwp290
[16] A. Klink, L. Tryggvadottir, F. Bray, M. Gislum, T. Hakulinen, H. H. Storm, et al., “Trends in the Survival of Patients Diagnosed with Cancer in Female Genital Organs in the Nordic Countries 1964-2003 Followed Up To The End Of 2006,” Acta Oncologica, Vol. 49, No. 5, 2010, pp. 632-643. doi:10.3109/02841861003691945
[17] L. Minelli, F. Stracci, S. Prandini, I. F. Moffa and R. F. La, “Gynaecological Cancers in Umbria (Italy): Trends of Incidence, Mortality and Survival, 1978-1998,” European Journal of Obstetrics & Gynecology, Vol. 115, No.1, 2004, pp. 59-65. doi:10.1016/j.ejogrb.2003.11.026
[18] N. K. Lee, M. K. Cheung, J. Y. Shin, A. Husain, N. N. Teng, J. S. Berek, et al., “Prognostic Factors for Uterine Cancer in Reproductive-Aged Women,” Obstetrics & Gynecology, Vol. 109, No. 3, pp. 655-662. doi:10.1097/01.AOG.0000255980.88205.15
[19] L. S. Cook, L. M. Kmet, A. M. Magliocco and N. S. Weiss, “Endometrial Cancer Survival among US Black and White Women by Birth Cohort,” Epidemiology, Vol. 17, No. 4, 2006, pp. 469-472. doi:10.1097/01.ede.0000221026.49643.cf
[20] M. E. Sherman and S. S. Devesa, “Analysis of Racial Differences in Incidence, Survival, and Mortality for Malignant Tumors of the Uterine Corpus,” Cancer, Vol. 98, No. 1, 2003, pp. 176-186. doi:10.1002/cncr.11484
[21] K. Aoki, J. Sun, A. Kono and J. Misumi, “Age-Related Characteristics of Uterine Cancer Mortality in Japan,” Archives of Gynecology and Obstetrics, Vol. 273, No. 2, 2005, pp. 110-114. doi:10.1007/s00404-005-0044-8
[22] L. K. Smith, P. C. Lambert and D. R. Jones, “Up-to-Date Estimates of Long-Term Cancer Survival in England and Wales,” British Journal of Cancer, Vol. 89, No. 1, 2003, pp. 74-76. doi:10.1038/sj.bjc.6600976
[23] M. A. Crosby, J. D. Tward, A. Szabo, C. M. Lee and D. K. Gaffney, “Does Brachytherapy Improve Survival in Addition to External Beam Radiation Therapy in Patients with High Risk Stage I and II Endometrial Carcinoma?” American Journal of Clinical Oncology, Vol. 33, No. 4, 2010, pp. 364-349. doi:10.1097/COC.0b013e3181b0c266
[24] J. M. Straughn, Jr., T. M. Numnum, L. C. Kilgore, E. E. Partridge, J. L. Phillips, M. Markman, et al., “The Use of Adjuvant Radiation Therapy in Patients with Intermediate-Risk Stages IC And II Uterine Corpus Cancer: A Patient Care Evaluation Study from the American College of Surgeons National Cancer Data Base,” Gynecologic Oncology, Vol. 99, No. 3, 2005, pp. 530-535. doi:10.1016/j.ygyno.2005.08.034
[25] C. M. Lee, A. Szabo, D. C. Shrieve, O. K. Macdonald and D. K. Gaffney, “Frequency and Effect of Adjuvant Radiation Therapy among Women with Stage I Endometrial Adenocarcinoma,” Journal of the American Medical Association, Vol. 295, No 4, 2006, pp. 389-397. doi:10.1001/jama.295.4.389